Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Personalized Medicine in NSCLC

February 27th 2015

Clinical Utility of PD-L1 as a Biomarker in Lung Cancer

February 27th 2015

Immunotherapy in Non-Small Cell Lung Cancer

February 27th 2015

Intricacies of Checkpoint Inhibition in NSCLC

February 27th 2015

Promise of Immunotherapy in Lung Cancer

February 27th 2015

Checkpoint Inhibition for Mesothelioma, Thymic Malignancies

February 27th 2015

Necitumumab in Squamous NSCLC

February 27th 2015

Ramucirumab in Metastatic NSCLC

February 27th 2015

Maintenance Combination Therapy in NSCLC

February 27th 2015

Chemotherapy Regimens in Metastatic NSCLC

February 27th 2015

Treating Driver Mutation Negative NSCLC

February 27th 2015

Novel ALK Inhibitors in NSCLC With Brain Metastases

February 27th 2015

Treatments for ALK-Positive NSCLC

February 27th 2015

ALK Inhibition in NSCLC

February 27th 2015

Types of EGFR Therapy in NSCLC

February 27th 2015

Overcoming EGFR Inhibitor Resistance in NSCLC

February 27th 2015

Bevacizumab in Non-Small Cell Lung Cancer

February 27th 2015

First-Line Therapy in EGFR-Mutant Lung Cancer

February 27th 2015

Molecular Testing in Non-Small Cell Lung Cancer

February 27th 2015

Future Treatments for Triple-Negative Breast Cancer

February 25th 2015